Watch the on-demand session.
Learn from Dr. Tobias Moll (University of Sheffield) as he shares research on using antisense oligonucleotides (ASOs) to target CCDC146 as a potential broad-spectrum therapeutic strategy for ALS.
Presented at EditCo Draughts & Discoveries 2026 in Cambridge, UK, this session highlights how reducing CCDC146 can improve neuron survival across different ALS models, offering new insights into RNA-based therapies.